Go to the list of all blogs
Serhii Bondarenko's Avatar
published in Blogs
Jul 20, 2026
ExxonMobil (XOM) +6.9% Recovery: Oil Price Volatility and Q2 Earnings Tailwinds

ExxonMobil (XOM) +6.9% Recovery: Oil Price Volatility and Q2 Earnings Tailwinds

Key Takeaways

  • XOM shares closed at $147.36 on July 17, 2026, reflecting a 6.9% gain over the trailing 30-day period as the stock recovered from a mid-June selloff that briefly took prices below $135.
  • ExxonMobil signaled that Q2 2026 upstream earnings will benefit by $3.5–$3.9 billion from elevated crude prices, with additional margin gains of $3.0–$3.6 billion across its Energy Products and Chemical Products segments.
  • The Middle East conflict—centered on U.S.-Iran tensions and the effective closure of the Strait of Hormuz—has been the dominant catalyst, driving Brent crude to average $96.68 per barrel in Q2, a 23% sequential increase.
  • Despite powerful Q2 profit tailwinds, crude prices have retreated roughly 40% from their April 2026 peak near $125 per barrel, injecting significant uncertainty into the second-half earnings trajectory.
  • Wall Street consensus rates XOM a Moderate Buy with an average price target of $164.45, though individual analyst targets range broadly from $154 to $185, reflecting deep disagreement on the durability of war-related earnings.

Where XOM Stands in the Current Market

ExxonMobil shares have been navigating a volatile stretch defined by opposing forces: a historic surge in oil prices driven by geopolitical disruption, and growing caution as those same prices retreat. The stock touched a 52-week high of $176.41 earlier in 2026 before pulling back through the spring and early summer, mirroring the broader energy sector's decline of 14.5% since March 31, according to FactSet data. As of mid-July, XOM is trading near $147, roughly in line with its 50-day and 200-day moving averages, with a market capitalization approaching $612 billion. Institutional ownership remains high at 61.8%, and the company's ultra-low beta of 0.17 underscores its defensive characteristics even amid pronounced commodity swings.

ExxonMobil’s Business Overview and Competitive Position

ExxonMobil Corporation is one of the world's largest integrated oil and gas companies, operating across the full energy value chain. Its Upstream segment explores for and produces crude oil and natural gas, anchored by low-cost advantaged assets in the Permian Basin and Guyana. The Energy Products, Chemical Products, and Specialty Products segments cover refining, petrochemical manufacturing, lubricants, and a growing portfolio of lower-emission businesses including carbon capture, hydrogen, and lithium. The company markets fuels under the Exxon, Mobil, and Esso brands, and its Mobil 1 motor oil is among the most recognized consumer products in the industry. With a debt-to-equity ratio of just 0.13 and 42 consecutive years of annual dividend growth, ExxonMobil is widely regarded as the financially strongest supermajor, built to perform through disruption and across market cycles.

Recent Developments Driving the Stock

The most significant recent development for ExxonMobil has been its July 7 regulatory filing previewing Q2 2026 results. The company disclosed that higher crude oil prices are expected to add $3.5–$3.9 billion to upstream earnings versus Q1, while improved refining and chemical margins should contribute an additional $3.0–$3.6 billion. These tailwinds are partly offset by roughly $1.2 billion in losses from Middle East production disruptions and shutdowns tied to the Strait of Hormuz conflict. Separately, XOM expects to record approximately $2.6 billion in derivative gains linked to physical cargo deliveries—largely the unwinding of $3.9 billion in unfavorable timing effects booked in Q1.

On the analyst front, Bank of America upgraded XOM from Neutral to Buy with a $154 target on June 16, while TD Cowen reduced its target from $172 to $155 on July 2, maintaining a Buy rating. Wells Fargo holds the Street-high target at $185, while Barclays and Bernstein remain at $182. The company's Q1 2026 results, reported May 1, showed adjusted EPS of $1.16 versus consensus of $0.98 on revenue of $83.16 billion. Underlying earnings reached $8.8 billion, up from $7.6 billion year-over-year, supported by record Guyana production and the first LNG cargo from the Golden Pass Train 1 facility. The quarterly dividend of $1.03 per share was paid on June 10, representing a 2.8% annualized yield.

Exploring Systematic Approaches with AI Trading Tools

In my analysis of energy names like XOM, I sometimes review data-driven strategies to cross-check my own views on volatility and trends. Tickeron’s Trending AI Robots page provides a window into algorithmic approaches that trade thousands of tickers, surfacing only the highest-performing bots with transparent performance metrics. These range from short-term swing strategies to longer-term trend-following ones, which can offer additional perspective when evaluating commodity-driven stocks.

2026 Outlook and Key Items to Monitor

The July 31 earnings release stands as the most immediate catalyst for XOM. Consensus estimates compiled by LSEG project adjusted earnings of approximately $15.7 billion for Q2—roughly triple the Q1 figure—with EPS estimates having surged to $3.63 from $2.42 since March 31, per FactSet. Beyond the print, investors will scrutinize management's commentary on the Strait of Hormuz situation, given that the channel handles roughly one-fifth of global oil flows. Any credible path toward reopening could pressure crude prices and, by extension, ExxonMobil's upstream earnings trajectory into the second half.

Longer-term structural drivers remain intact. Guyana production continues to set records, the Golden Pass LNG facility is ramping toward full capacity, and the company's low-carbon ventures are gradually maturing. However, political headwinds around elevated U.S. gasoline prices and possible White House pressure on the industry add a layer of regulatory risk. With analyst targets spanning a $31 range, the market is clearly pricing in a wide distribution of outcomes. Monitoring crude price stability, Hormuz developments, and post-earnings guidance revisions will be critical for understanding whether XOM can sustain its earnings momentum into 2027.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: XOM

Contributor

Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.


XOM in upward trend: price rose above 50-day moving average on July 17, 2026

XOM moved above its 50-day moving average on July 17, 2026 date and that indicates a change from a downward trend to an upward trend. In of 47 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The 10-day moving average for XOM crossed bullishly above the 50-day moving average on July 23, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where XOM advanced for three days, in of 370 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 316 cases where XOM Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for XOM moved out of overbought territory on July 31, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 43 similar instances where the indicator moved out of overbought territory. In of the 43 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 69 cases where XOM's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Momentum Indicator moved below the 0 level on August 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on XOM as a result. In of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for XOM turned negative on August 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XOM declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

XOM broke above its upper Bollinger Band on July 13, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 31, placing this stock better than average.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. XOM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.523) is normal, around the industry mean (2.244). P/E Ratio (26.067) is within average values for comparable stocks, (19.542). Projected Growth (PEG Ratio) (1.212) is also within normal values, averaging (1.259). Dividend Yield (0.026) settles around the average of (0.039) among similar stocks. P/S Ratio (2.025) is also within normal values, averaging (2.139).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are ExxonMobil Holdings Corporation (NYSE:XOM), Chevron Corp (NYSE:CVX), Petroleo Brasileiro Sa-Petrobras ADS (REP 1 Common Share) (NYSE:PBR), BP plc (NYSE:BP), Suncor Energy (NYSE:SU), YPF Sociedad Anonima (NYSE:YPF).

Industry description

Integrated oil companies are involved across nearly the entire oil value chain – from upstream operations like exploration and production, to downstream functions of refining and marketing. Exxon Mobil Corporation, Chevron Corporation and BP are major integrated oil companies. Their bottom lines’ response to crude oil prices could depend on the proportion of upstream vs. downstream businesses; for example, if a company has substantial downstream business, the adverse impact on their upstream business due to falling crude prices could be mitigated by benefits to its downstream business.

Market Cap

The average market capitalization across the Integrated Oil Industry is 115B. The market cap for tickers in the group ranges from 39.76K to 628.5B. XOM holds the highest valuation in this group at 628.5B. The lowest valued company is PGAS at 39.76K.

High and low price notable news

The average weekly price growth across all stocks in the Integrated Oil Industry was -3%. For the same Industry, the average monthly price growth was 10%, and the average quarterly price growth was 21%. DEC experienced the highest price growth at 3%, while SKYQ experienced the biggest fall at -9%.

Volume

The average weekly volume growth across all stocks in the Integrated Oil Industry was -4%. For the same stocks of the Industry, the average monthly volume growth was -29% and the average quarterly volume growth was -17%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 46
P/E Growth Rating: 55
Price Growth Rating: 42
SMR Rating: 62
Profit Risk Rating: 30
Seasonality Score: -30 (-100 ... +100)
View a ticker or compare two or three
XOM
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a distributer of crude oil, natural gas and petroleum products

Industry IntegratedOil

Profile
Details
Industry
Integrated Oil
Address
22777 Springwoods Village Parkway
Phone
+1 972 940-6000
Employees
61500
Web
https://www.exxonmobil.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.